Abstract
BackgroundDespite significant progress in the development of T cell-engaging therapies for various B-cell malignancies, a high medical need remains for the refractory disease setting, often characterized by suboptimal target levels.MethodsTo...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have